hVIVO plc (FRA:CRO)

Germany flag Germany · Delayed Price · Currency is EUR
0.0770
-0.0040 (-4.94%)
At close: Sep 26, 2025
-4.94%
Market Cap62.34M
Revenue (ttm)63.54M
Net Income (ttm)6.16M
Shares Outn/a
EPS (ttm)0.01
PE Ratio10.11
Forward PEn/a
Dividend0.00 (3.08%)
Ex-Dividend DateMay 15, 2025
Volume13,283
Average Volumen/a
Open0.0770
Previous Close0.0810
Day's Range0.0770 - 0.0770
52-Week Range0.0770 - 2.6840
Betan/a
RSI43.44
Earnings DateSep 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]

Industry Commercial Physical and Biological Research
CEO Yamin Khan
Employees 301
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CRO
Full Company Profile

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial numbers in GBP Financial Statements

News

There is no news available yet.